SCHEMBL4959331

SCHEMBL4959331

O=S(=O)(Cc1ccccc1Br)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSIP1 O75475 1/20 0.48
PLCG1 P19174 1/20 0.44
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
PLA2G7 Q13093 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529819 0.84 MAPT (0.41) PSIP1PLCG1MAPTSMN1; SMN2NPC1
SCHEMBL1714597 0.80 PSIP1 (0.48) PSIP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL29594496 0.80 PSIP1 (0.48) PSIP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL22116771 0.79 LMNA (0.51) MAPTLMNACA1CA2CA9
SCHEMBL3533079 0.79 HTT (0.43) PSIP1PLCG1MAPTSMN1; SMN2NPC1
SCHEMBL5661830 0.79 TAAR1 (0.46) PLCG1LMNACA12CA1CA2
SCHEMBL27575272 0.78 PSIP1 (0.47) PSIP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL11922695 0.78 PSIP1 (0.61) PSIP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL28245555 0.77 CYP2A6 (0.43) PLCG1LMNACA12CA1CA2
SCHEMBL2808506 0.76 PSIP1 (0.54) PSIP1MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104531397-A Cleaning solution for sheet glass substrate thinning pre-cleaning, and application thereof HUIJING DISPLAY TECHNOLOGY SUZHOU CO LTD 2015-04-22 CN claimed
CN-104531397-A Cleaning solution for sheet glass substrate thinning pre-cleaning, and application thereof HUIJING DISPLAY TECHNOLOGY SUZHOU CO LTD 2015-04-22 CN disclosed
EP-1383733-B1 PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PROD INC (US) 2008-03-05 EP disclosed
CN-1321107-C Process for the preparatino of 1,3-substituted indenes and aryl-fused azapolycyclic compounds PFIZER PROD INC (US) 2007-06-13 CN disclosed
US-7186870-B2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds PFIZER INC (US) 2007-03-06 US disclosed
US-7186870-B2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds PFIZER INC (US) 2007-03-06 US disclosed
US-7186870-B2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds PFIZER INC (US) 2007-03-06 US disclosed
US-7091372-B2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds PFIZER INC (US) 2006-08-15 US disclosed
US-20060079707-A1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds PFIZER INC 2006-04-13 US disclosed
CN-1503781-A Process for preparing 1, 3-substituted indenes and aryl-fused azapolycyclic compounds �Ʒ� 2004-06-09 CN disclosed
EP-1383733-A2 PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS Pfizer Products Inc. (US) 2004-01-28 EP disclosed
US-20030060624-A1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds PFIZER INC. 2003-03-27 US disclosed
WO-2002085843-A2 PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079707-A1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds CYP1B1, AZI2, CYP1A1 PSIP1 2252/4885PLCG1 1913/4885MAPT 4605/4885
US-20030060624-A1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds INTS6, CYP1B1, CYP1A2 PSIP1 916/4885PLCG1 1027/4885MAPT 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.